Akari Therapeutics Plc

For the period ended Mar 31, 2026. Filed May 19, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 19, 2026

AKTX$7.66+3.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(Amounts in thousands, except share and per share data)

	March 31,	December 31,
	2026	2025
ASSETS
Current assets:
Cash	$2,768	$5,203
Restricted cash	60	60
Prepaid expenses	731	185
Other current assets	30	14
Total current assets	3,589	5,462
Goodwill	—	8,430
Other intangible assets	30,300	34,000
Total assets	$33,889	$47,892
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$8,641	$8,770
Accrued expenses	3,328	2,342
Convertible notes, net	683	673
Notes payable, net	49	81
Warrant liabilities	17	61
Other current liabilities	697	424
Total current liabilities	13,415	12,351
Derivative liability	—	230
Other non-current liabilities	—	31
Deferred tax liability	6,094	6,952
Total liabilities	19,509	19,564
Commitments and contingencies (Note 13)
Shareholders’ equity:
Share capital of $0.000000005 par value
Authorized: 761,963,201,733 ordinary shares at March 31, 2026, and December 31, 2025; issued and outstanding: 91,567,009,533 and 90,536,879,533 ordinary shares at March 31, 2026, and December 31, 2025, respectively	—	—
Additional paid-in capital	234,811	234,318
Capital redemption reserve	59,342	59,342
Accumulated other comprehensive loss	(768)	(782)
Accumulated deficit	(279,005)	(264,550)
Total shareholders’ equity	14,380	28,328
Total liabilities and shareholders’ equity	$33,889	$47,892

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.